Harbor Capital Advisors Inc. Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Harbor Capital Advisors Inc. grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 117.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 56,164 shares of the medical instruments supplier's stock after buying an additional 30,389 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.11% of Haemonetics worth $4,514,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of HAE. Quarry LP purchased a new position in Haemonetics in the second quarter worth about $39,000. Covestor Ltd raised its holdings in shares of Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Haemonetics during the second quarter valued at approximately $82,000. Canada Pension Plan Investment Board purchased a new position in shares of Haemonetics during the second quarter valued at approximately $83,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Haemonetics during the first quarter valued at approximately $86,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Citigroup decreased their price objective on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a report on Thursday, August 22nd. Barrington Research reissued an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a report on Monday, September 23rd. Bank of America assumed coverage on shares of Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price objective for the company. BTIG Research assumed coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They set a "buy" rating and a $112.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and set a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $106.14.

Haemonetics Price Performance

Shares of HAE traded up $2.05 during mid-day trading on Monday, reaching $73.53. The stock had a trading volume of 607,883 shares, compared to its average volume of 538,092. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of 32.05, a PEG ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The business has a fifty day moving average of $75.46 and a 200 day moving average of $82.74. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business's revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.05 earnings per share. Equities analysts predict that Haemonetics Co. will post 4.57 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.